Veeva Completes Study Migrations to Veeva Vault EDC for Top Biopharma
- Successful migration of 25 ongoing clinical studies is an industry first
- Large study with over 500 research sites and 7,000 patients migrated to Vault EDC
- Vault EDC's proprietary migration capability enables secure migration with minimal disruption
- None.
Insights
The migration of 25 ongoing clinical studies from a legacy electronic data capture (EDC) system to Veeva Vault EDC by a top 20 biopharma company represents a significant shift within the pharmaceutical industry. This change suggests a confidence in newer technologies that promise to streamline research processes and potentially reduce costs associated with clinical trials. As these studies encompass a large study with extensive research sites and patients, the successful migration indicates a robustness in Veeva's technology that can handle vast amounts of data securely and efficiently.
From a market perspective, this could lead to an increased adoption rate of Veeva's services among other biopharma companies, as industry peers often follow suit after a successful case study. If Veeva Systems can demonstrate cost savings and improved data management, it may become a preferred provider, which could impact its market share and revenue growth positively. Investors should monitor Veeva's customer acquisition post-migration and any changes in their financial projections as a result of this development.
The transition to Veeva Vault EDC is notable for its potential to enhance the efficiency and reliability of data capture in clinical trials. The migration of such a large volume of data points and forms without significant disruption is a testament to the robustness of the Veeva platform. For medical research, the implications are profound. Improved data management systems can lead to faster trial completion times, better data integrity and a more streamlined regulatory submission process.
It's important to consider that if Vault EDC can indeed provide a better site experience as claimed, it might improve the quality of data collected and the satisfaction of research personnel. This could lead to a higher quality of clinical trials and potentially accelerate the time to market for new drugs. The long-term impact on the biopharma industry could be substantial, influencing how companies allocate resources to data management solutions.
The financial implications of Veeva Systems' announcement can be multifaceted. Firstly, for Veeva, the successful migration could signal an opportunity for upselling and cross-selling additional services to existing and new clients. The ability to reduce fees, as mentioned, may also allow Veeva to attract price-sensitive customers. On the client side, the reduction in operational costs through standardization and decommissioning of legacy systems could lead to improved profit margins.
Investors should evaluate the potential for Veeva's expansion within the EDC market and its impact on earnings. The scalability of Veeva's solutions could lead to margin improvements as the company onboards more clients. Additionally, the move by a top 20 biopharma company might set a precedent, potentially creating a ripple effect throughout the industry, leading to a reassessment of the competitive landscape. The market will be watching for any shifts in market share among EDC providers and any response from competitors.
In an industry first, all ongoing studies migrated to Vault EDC from legacy EDC
Life sciences companies have historically avoided migrating studies due to technical challenges, complex data models, and risk concerns. Vault EDC's proprietary migration capability enables Veeva Services to migrate ongoing studies securely with minimal disruption. With this top 20 biopharma, Vault EDC was used to migrate more than 55 million data points and five million forms safely and efficiently.
"Locked down legacy systems and perceived risks have made the topic of migrating studies a non-starter," said Drew Garty, chief technology officer, Veeva Vault CDMS. "Biopharma companies can now reliably migrate ongoing studies from their legacy applications to Veeva Vault EDC with a repeatable approach that can reduce fees, drive standardization, and provide a better site experience."
Vault EDC's migration capability enables customers to decommission legacy EDC systems while advancing clinical data management. To learn more about Vault EDC, visit veeva.com/VaultEDC.
About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking Statements
This release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find here (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
deivis.mercado@veeva.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/veeva-completes-study-migrations-to-veeva-vault-edc-for-top-biopharma-302036877.html
SOURCE Veeva Systems
FAQ
How many clinical studies were migrated to Veeva Vault EDC from a legacy EDC application?
What is the ticker symbol for Veeva Systems?
What is the main benefit of migrating studies to Veeva Vault EDC?
Who announced the migration of clinical studies to Veeva Vault EDC?
What was the role of Veeva Services in the migration of clinical studies to Veeva Vault EDC?
What is the significance of the migration of 25 ongoing clinical studies to Veeva Vault EDC?
